Quarterly Report (10-q)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended July 31, 2015.

[ ] Transition report under Section 13 or 15(d) of the Exchange Act

For the transition period from ____________ to ____________.

Commission file number 000-28761

CARDIOGENICS HOLDINGS INC.

(Exact name of registrant as specified in its Charter)

Nevada

88-0380546

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

6295 Northam Drive, Unit 8

Mississauga, Ontario L4V 1WB

(Address of Principal Executive Offices)

(905) 673-8501

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer and “smaller reporting company” in Rule 12b-2 or the Exchange Act. (Check one):

	Large Accelerated filer	[ ]	Accelerated Filer	[ ]

	Non-Accelerated Filer	[ ]	Smaller Reporting Company	[X]
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yes [ ] No [X]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

As of September 18, 2015 the Registrant had the following number of shares of its capital stock outstanding: 80,566,160 shares of Common Stock and 1 share of Series 1 Preferred Voting Stock, par value $0.0001, representing 13 exchangeable shares of the Registrant’s subsidiary, CardioGenics ExchangeCo Inc., which are exchangeable into 24,176,927 shares of the Registrant’s Common Stock.

CARDIOGENICS HOLDINGS INC.

FORM 10-Q

For the Quarter Ended July 31, 2015

INDEX

		Page

*Part I. Financial Information*
		F-1
Item 1: Financial Statements (Unaudited)

Condensed Consolidated Balance Sheets at July 31, 2015 (Unaudited) and October 31, 2014		F-1

Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months Ended July 31, 2015 and 2014		F-2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) for the Three and Nine Months Ended July 31, 2015 and 2014		F-3

Condensed Consolidated Statement of Changes in Deficiency (Unaudited) for the Nine Months ended July 31, 2015		F-4

Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months ended July 31, 2015 and 2014		F-5

Notes to Condensed Consolidated Financial Statements (Unaudited)		F-6

Item 2: Management’s Discussion and Analysis of Financial Conditions and Results of Operations		3

Item 3: Quantitative and Qualitative Disclosures About Market Risk		6

Item 4: Controls and Procedures		6

*Part II. Other Information*

Item 1: Legal Proceedings		7

Item 1A: Risk Factors		7

Item 2: Unregistered Sales of Equity Securities and Use of Proceeds		7

Item 3: Defaults Upon Senior Securities		7

Item 4: Mine Safety Disclosures		7

Item 5: Other Information		7

Item 6: Exhibits		8

Signatures		9

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

CardioGenics Holdings Inc.

Condensed Consolidated Balance Sheets

	July 31, 2015			October 31, 2014
		(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	49,240		$	70,676
Accounts Receivable		196			228
Refundable Taxes Receivable		2,465			2,625
Total current assets		51,901			73,529
Property and Equipment, net		36,740			42,693
Deposits and Prepaid Expenses		41,567			45,576
Patents, net		104,740			108,132

Totals	$	234,948		$	269,930

Liabilities and Deficiency

Current liabilities:
Accounts Payable and Accrued Expenses	$	981,199		$	1,020,809
Funds Held in Trust for Redemption of Class B Common Shares		4			4
Due to Shareholders		107,645			131,052
Notes Payable, net of debt discount		133,843			71,863
Derivative Liability on Notes Payable		645,594			201,260
Total current liabilities and total liabilities		1,868,285			1,424,988

Commitments and contingencies

Deficiency
Preferred stock; par value $.0001 per share, 50,000,000 shares authorized, none issued		-			-
Common stock; par value $.00001 per share; 150,000,000 shares authorized, 76,060,520 and 47,383,379 common shares and 24,176,927 and 24,176,927 exchangeable shares issued and outstanding as of July 31, 2015 and October 31, 2014		979			692
Additional paid-in capital		47,400,545			46,505,954
Accumulated deficit		(49,186,943	)		(47,637,746	)
Accumulated other comprehensive loss		152,082			(23,958	)
Total deficiency		(1,633,337	)		(1,155,058	)

Totals	$	234,948		$	269,930

See notes to condensed consolidated financial statements.

F-1

CardioGenics Holdings Inc.

Condensed Consolidated Statements of Operations (unaudited)

For the Three and Nine Months Ended July 31, 2015 and 2014

	For the Three Months Ended July 31,						For the Nine Months Ended July 31,
	2015			2014			2015			2014

Revenue	$	-		$	-		$	-		$	-

Operating Expenses
Depreciation and Amortization of Property and Equipment		2,061			2,740			5,953			8,168
Amortization of Patent Application Costs		788			1,724			5,449			5,140
General and Administrative		46,626			107,751			262,141			375,796
Research and Product Development, Net of Investment Tax Credits		50,430			85,241			186,867			275,916
Total operating expenses		99,905			197,456			460,410			665,020
Operating Loss		(99,905	)		(197,456	)		(460,410	)		(665,020	)

Other Expenses (Income)
Interest Expense and Bank Charges (Net)		130,118			142,256			392,511			379,836
Loss on Change in Fair Value of Derivative Liability		314,345			246,430			643,194			247,249
Loss (Gain) on Foreign Exchange Transactions		67,122			(20,515	)		53,082			21,664

Total other expenses(income)		511,585			368,171			1,088,787			648,749

Net Loss	$	(611,490	)	$	(565,627	)	$	(1,549,197	)	$	(1,313,769	)

Basic and Fully Diluted Net Loss per Common Share Shareholders	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.02	)
Weighted-average shares of Common Stock outstanding		98,626,734			60,938,316			86,990,095			60,260,456

See notes to condensed consolidated financial statements.

F-2

CardioGenics Holdings Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)

For the Three and Nine Months Ended July 31, 2015 and 2014

	Three Months Ended						Nine Months Ended
	July 31,						July 31,
	2015			2014			2015			2014

Net (loss)	$	(611,490	)	$	(565,627	)	$	(1,549,197	)	$	(1,313,769	)
Other comprehensive income (loss), currency translation adjustments		105,653			(10,262	)		176,040			66,415

Comprehensive (loss)	$	(505,837	)	$	(575,889	)	$	(1,373,157	)	$	(1,247,354	)

See notes to condensed consolidated financial statements.

F-3

CardioGenics Holdings Inc.

Condensed Consolidated Statements of Changes in Deficiency (unaudited)

For the Nine Months Ended July 31, 2015

										Accumulated
					Additional					Other
	Common Stock				Paid-in		Accumulated			Comprehensive			Total
	Shares		Amount		Capital		Deficit			Income (Loss)			(Deficiency)
Balance November 1, 2014		71,560,306	$	692	$	46,505,954	$	(47,637,746	)	$	(23,958	)	$	(1,155,058	)
Issuance of common shares on conversion of notes payable November 2014		589,679		6		22,528								22,534
Issuance of common shares on conversion of notes payable December 2014		2,977,637		30		32,230								32,260
Issuance of common shares on conversion of notes payable January 2015		7,349,902		73		83,051								83,124
Issuance of common shares on conversion of shareholder’s loan February 2015		227,273		2		22,854								22,856
Issuance of common shares on conversion of notes payable February 2015		4,684,409		47		40,995								41,042
Issuance of common shares on conversion of notes payable March 2015		3,039,913		29		23,525								23,554
Issuance of common shares for services rendered March 2015		250,000		3		7,497								7,500
Issuance of common shares on conversion of notes payable April 2015		718,390		7		10,720								10,727
Issuance of common shares on conversion of notes payable May 2015		5,894,104		59		51,301								51,360
Issuance of common shares on conversion of notes payable June 2015		1,345,834		15		18,470								18,485
Issuance of common shares for cash May 2015		1,600,000		16		39,984								40,000
Settlement of derivative value of notes payable on conversion to common shares						541,436								541,436

Comprehensive Income (Loss):
Net Loss								(1,549,197	)					(1,549,197	)
Other Comprehensive Income
Currency Translation Adjustment											176,040			176,040
Total Comprehensive Income (Loss)								(1,549,197	)		176,040			(1,373,157	)
Balance July 31, 2015		100,237,447	$	979	$	47,400,545	$	(49,186,943	)	$	152,082		$	(1,633,337	)

See notes to condensed consolidated financial statements.

F-4

CardioGenics Holdings Inc.

Condensed Consolidated Statements of Cash Flows (unaudited)

Nine Months Ended July 31, 2015 and 2014

	Nine Months Ended July 31,
	2015			2014

Cash flows from operating activities:
Consolidated net income (loss)	$	(1,549,197	)	$	(1,313,769	)
Adjustments to reconcile consolidated net income (loss) to net cash used in operating activities:
Depreciation and amortization		5,953			8,168
Amortization of Patent Application Costs		5,449			5,140
Loss on Change in Value of Derivative Liability		643,194			247,249
Interest and Discount on Notes Payable		376,248			123,521
Amortization of Discount on Debentures Payable		-			186,489
Common stock issued for services rendered		7,500			25,000
Changes in working capital items:
Accounts receivable		32			10
Deposits and Prepaid Expenses		(1,241	)		2,094
Refundable Taxes Receivable		160			(580	)
Government Grants and Investment Tax Credits Receivable		-			(11,218	)
Accounts Payable and Accrued Expenses		38,416			186,909
Cash used in operating activities		(473,486	)		(540,987	)

Cash flows from investing activities:
Patent Application Costs		(2,057	)		-
Cash used in investing activities		(2,057	)		-

Cash flows from financing activities:
Due to Shareholders		-			22,957
Payment on Notes Payable		(4,291	)		-
Proceeds from Notes Payable		255,000			180,000
Issue of Common Shares for Cash		40,000			50,000
Cash provided by financing activities		290,709			252,957

Effects of exchange rate changes on cash		163,798			39,284

Net decrease in cash and cash equivalents		(21,036	)		(248,746	)

Cash and cash equivalents, beginning of period		70,276			263,103

Cash and cash equivalents, end of period	$	49,240		$	14,357

See notes to condensed consolidated financial statements.

F-5

CardioGenics Holdings Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

July 31, 2015 and 2014

1.	Nature of Business

CardioGenics Inc. (“CardioGenics”) was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development.

CardioGenics’ revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing.

On October 27, 2009, the name of the Company was changed from JAG Media Holdings, Inc. to CardioGenics Holdings, Inc.

2.	Basis of Presentation

In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings Inc. and its subsidiaries under generally accepted accounting principles in the United States (“US GAAP”) as of July 31, 2015, their results of operations for the three and nine months ended July 31, 2015 and 2014, changes in deficiency for the nine months ended July 31, 2015 and cash flows for the nine months ended July 31, 2015 and 2014. CardioGenics Holdings Inc. and its subsidiaries are referred to together herein as the “Company”. Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these consolidated financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements, notes to consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2014 and 2013 (the “Audited Financial Statements”) included in the Company’s Form 10-K that was previously filed with the SEC on February 12, 2015 and from which the October 31, 2014 consolidated balance sheet was derived.

The results of the Company’s operations for the nine months ended July 31, 2015 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2015.

The accompanying condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at July 31, 2015 of approximately $49.2 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements, management’s plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.

F-6

CardioGenics Holdings Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

July 31, 2015 and 2014

While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

3.	Summary of Significant Accounting Policies.

Derivative Instruments

The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date.

Beneficial Conversion Charge

The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.

4.	Income Taxes

Based on the Company’s evaluation, management has concluded that there are no significant tax positions requiring recognition in the condensed interim consolidated financial statements.

The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of July 31, 2015 approximated $7,561,000 which will expire from 2015 through 2033. All fiscal years as originally filed have been assessed. Claims relating to research and development credits are open for review for the fiscal years ended October 2014 and 2013.

A research and development tax credit for 2012 for which the Company received a refund of $81,460 is being refuted by Canadian taxation authorities. The Company is disputing the position taken by the taxation authorities, but has established a reserve against possible repayment.

F-7

CardioGenics Holdings Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

July 31, 2015 and 2014

Returns for the years 2008 through 2014 are yet to be filed. As of July 31, 2015, the Company believes it has net operating loss carryforwards from US sources of approximately $46,927,000 available to reduce future Federal taxable income which will expire from 2020 through 2033.

For the nine months ended July 31, 2015 and 2014, the Company’s effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

5.	Notes Payable

On November 19, 2012, the Company entered into an agreement (“Line”) with JMJ Financial (“Lender”) whereby the Company may borrow up to $350,000 from the Lender in increments of $50,000. The Line is subject to an original issue discount of $50,000. Advances under the Line (“Notes”) have a maturity date of one year from the date of the advance. If the advance is repaid within three months, the advance is interest free. If not repaid within three months, the advance may not be repaid before maturity and carries interest at 5%. The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion. Unless agreed in writing by the parties, at no time will the Lender convert any amount owing under the Line into common stock that would result in the Lender owing more than 4.99% of the common stock outstanding.

On May 23, 2014, the Company issued promissory notes (the “LG Notes”) to LG Capital Funding, LLC and Adar Bays, LLC (collectively the “Holders”) in the amount of $52,500 each bearing interest at 8% annually due May 23, 2015. The LG Notes and accrued interest may be converted into shares of the Common Stock of the Company at a 42% discount to the lowest closing bid with a 12 day look back. The LG Notes may be prepaid with the following penalties: (i) if the Notes are prepaid within 60 days of the issue date, then at 130% of the face amount plus any accrued interest; and, (ii) if the LG Notes are prepaid after 60 days after the issue date but less than 181 days after the issue date, then at 140% of the face amount plus any accrued interest. The LG Notes may not be prepaid after the 180^th day after issue. The LG Notes were all converted to common shares in 2015.

On November 12, 2014, the Company received $50,000 from Chicago Ventures in exchange for a note payable bearing interest at 10% due in one year, convertible into shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days.

On November 20, 2014, the Company reached a settlement with IBC Funds, LLC (“IBC”) whereby IBC agreed to pay $78,026 of the Company’s debts in exchange for the right to purchase shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days.

On December 15, 2014, the Company received $52,500 from LG Capital in exchange for a note payable bearing interest at 8% due in one year, convertible into shares in the Company’s common stock at a 42% discount from the lowest closing price of the common shares over the prior 15 days.

On March 5, 2015, the Company received $55,250 from Actus Private Equity Fund, LLC in exchange for a note payable bearing interest at 8% due November 26, 2015, convertible into shares in the Company’s common stock at a 40% discount from the average of the lowest two trading prices of the common shares over the prior 10 trading days.

On July 31, 2015, the Company received $52,500 from Adar Bays in exchange for a note payable bearing interest at 8% due in nine months, convertible into shares in the Company’s common stock at a 45% discount from the lowest closing price of the common shares over the prior 15 days.

F-8

CardioGenics Holdings Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

July 31, 2015 and 2014

A summary of the Notes Payable at July 31, 2015 and October 31, 2014 follows:

	July 31, 2015			October 31, 2014
Convertible Note Payable, due February 20, 2015	$	-		$	12,529
Convertible Notes Payable, due May 23, 2015		-			105,000
Convertible Note Payable, due June 23, 2016		21,449			40,000
Convertible Note Payable, due October 22, 2015		35,000			35,000
Convertible Note Payable, due November 12, 2015		35,000			-
Convertible IBC Funds, LLC Payable, due November 21, 2015		16,421			-
Convertible Note Payable, due December 15, 2015		26,500			-
Convertible Note Payable, due November 26, 2015		55,250			-
Convertible Note Payable, due March 25, 2016		23,000			-
Convertible Note Payable, due July 31, 2016		55,250
Debt Discount - value attributable to conversion feature attached to Notes, net of accumulated amortization of $133,843 and $71,863		(134,027	)		(120,666	)
Total		133,843			71,863
Less: Current portion		133,843			71,863
Total Long-term portion	$	-		$	-

As described in further detail in Note 6, “Derivative Liabilities”, the Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and as a derivative liability. Upon conversion of the Notes to Common Stock, any remaining unamortized discount is charged to financing expense.

6.	Derivative Liabilities

Convertible notes-embedded conversion features:

The Notes meet the definition of a hybrid instrument, as defined in ASC 815. The hybrid instrument is comprised of i) a debt instrument, as the host contract and ii) an option to convert the debentures into common stock of the Company, as an embedded derivative. The embedded derivatives derive their value based on the underlying fair value of the Company’s common stock. The embedded derivatives are not clearly and closely related to the underlying host debt instrument since the economic characteristics and risk associated with these derivatives are based on the common stock fair value.

The Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and a derivative liability. The Company has recognized a derivative liability of $645,594 at July 31, 2015. Accordingly, changes in the fair value of the embedded derivative are immediately recognized in earnings and classified as a gain or loss on the embedded derivative financial instrument in the accompanying condensed consolidated statements of operations. The Company recognized a loss of $643,194 in the fair value for the nine months ended July 31, 2015.

The Company estimated the fair value of the embedded derivatives using a Black Scholes model with the following assumptions: conversion price $0.012 per share according to the agreements; risk free interest rate of .11%; expected life of 1 year; expected dividend of zero; a volatility factor of 249% to 254%, as of July 31, 2015. The expected lives of the instruments are equal to the contractual term of the conversion option. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option.

F-9

CardioGenics Holdings Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

July 31, 2015 and 2014

7.	Fair Value Measurements

As defined by the ASC, fair value measurements and disclosures establish a hierarchy that prioritizes fair value measurements based on the type of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of hierarchy are described below:

	●	Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities.

	●	Level 2: Inputs other than quoted market prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets, such as interest rates and yield curves that are observable at commonly-quoted intervals.

	●	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions, as there is little, if any, related market activity.

The following table summarizes the financial liabilities measured at fair value on a recurring basis as of July 31, 2015, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value:

Quoted Prices in

Total Increase
(Reduction)

Active Markets for

Significant Other

Significant

in Fair Value

Balance Sheet

Identical Assets or

Observable Inputs

Unobservable

July 31, 2015

Recorded at

Location

Liabilities (Level 1)

(Level 2)

Inputs (Level 3)

Total

July 31, 2015

Liabilities:

Derivative liability – on Notes Payable

645,594

643,194

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the nine months ended July 31, 2015:

	2015			2014

Balance at beginning of period	$	201,260		$	99,702
Additions to derivative instruments		342,576			180,000
Change in fair value of derivative liabilities		643,194			247,249
Settlements		(541,436	)		(98,276	)
Balance at end of period	$	645,594		$	428,675

F-10

CardioGenics Holdings Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

July 31, 2015 and 2014

8.	Stock Based Compensation

Stock-based employee compensation related to stock options for the nine months ended July 31, 2015 and 2014 amounted to $-0-.

The following is a summary of the common stock options outstanding, granted, forfeited or expired and exercised under the Plan:

			Weighted Average
	Options		Exercise Price

Outstanding - October 31, 2013		30,000	$	0.90
Granted		-		-
Forfeited/Expired		-		-
Exercised		-		-
Outstanding - October 31, 2014		30,000	$	0.90
Granted		-		-
Forfeited/Expired		-		-
Exercised		-		-
Outstanding - July 31, 2015		30,000	$	0.90

Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at July 31, 2015.

9.	Warrants

Outstanding warrants are as follows:

	July 31, 2015		October 31, 2014

Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016		250,000		250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016		250,000		250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016		500,000		500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016		600,000		600,000
Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		750,000		750,000
Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		232,500		232,500
Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023		2,500,000		2,500,000
Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023		1,500,000		1,500,000
Issued to consultant on September 3, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including July 31, 2018		500,000		500,000
Issued to shareholder on October 29, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including October 29, 2016		250,000		250,000
Issued to shareholder on November 7, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016		125,000		-
Total Warrants outstanding		8,457,500		8,332,500

F-11

CardioGenics Holdings Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

July 31, 2015 and 2014

10.

Issuance of Common Stock

During the nine months ended July 31, 2015, the Company issued the following common shares:

Issued for cash consideration of $40,000			1,600,000
Issued for services rendered			250,000
Issued to shareholder on conversion of shareholders loan at $0.11 per share			227,273
Issued on conversion of Notes Payable			26,599,868
			28,677,141

11.

Net Loss per Share

The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings (loss) per share (EPS):

	Three Months Ended July 31,				Nine Months Ended July 31,
	2015		2014		2015		2014

Weighted-average shares - basic		98,626,734		60,938,316		86,990,095		60,260,456
Effect of dilutive securities		-		-		-		-
Weighted-average shares - diluted		98,626,734		60,938,316		86,990,095		60,260,456

Basic earnings (loss) per share “EPS” and diluted EPS for the three and nine months ended July 31, 2015 and 2014 have been computed by dividing the net income (loss) available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants and conversion of debt representing 28,350,458 and 15,367,845 incremental shares, respectively, have been excluded from the three and nine months ended July 31, 2015 and 2014 computation of diluted EPS as they are antidilutive given the net losses generated for the periods presented.

12.

Supplemental Disclosure of Cash Flow Information

	For the Nine Months Ended July 31,
	2015		2014

Cash paid during the year for:
Interest	$	16,263	$	12,352
Income taxes	$	-	$	-
Non-cash financing activities
Conversion of notes payable	$	283,086	$	73,501
Settlement of derivative liability	$	541,436	$	98,276
Issuance of shares on settlement of suit	$	-	$	189,000
Common share issued for services	$	7,500	$	-
Common shares issued for shareholder’s loan	$	22,856	$	-

F-12

CardioGenics Holdings Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

July 31, 2015 and 2014

13.

Commitments and contingent liabilities

Lawsuit

On June 3, 2015, JMJ Financial filed a suit in Florida court demanding payment of its outstanding note payable in the amount of $77,235 for failure to convert a portion of its note into 1,800,000 common shares. The Company has agreed to pay JMJ Financial cash monthly payments of $6,436 over the next eleven months or the equivalent number of common shares at the trading value at the payment due date. A payment of $6,436 was made in July 2015.

14.

Subsequent Events

	(i)	On August 21, 2015 the Company issued JMJ Financial 233,875 common shares in settlement of that month’s obligation under the lawsuit settlement.

	(ii)	On September 15, 2015 the Company issued JMJ Financial 232,860 common shares in settlement of that month’s obligation under the lawsuit settlement.

F-13

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read this Management’s Discussion and Analysis (“MD&A”) in combination with the accompanying unaudited condensed interim consolidated financial statements and related notes as well as the audited consolidated financial statements and the accompanying notes to the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) included within the Company’s Annual Report on Form 10-K filed on February 12, 2015.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed interim consolidated financial statements, which have been prepared in accordance with U.S. GAAP for interim financial statements filed with the Securities and Exchange Commission.

The preparation of these unaudited condensed interim consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, equipment, stock-based compensation, income taxes and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The accounting policies and estimates used as of October 31, 2014, as outlined in our previously filed Form 10-K, have been applied consistently for the nine months ended July 31, 2015.

Related Party Transactions

In February 2015, a shareholder’s loan in the amount of $22,856 was exchanged for 227,273 common shares.

Off-Balance Sheet arrangements

We are not party to any off-balance sheet arrangements.

Results of operations

Nine months ended July 31, 2015 as compared to nine months ended July 31, 2014

	Nine Months
	Ended July 31,
	2015			2014			$ Change

Revenue	$	-		$	-		$	-

Operating expenses:
Depreciation and amortization of property and equipment		5,953			8,168			2,215
Amortization of patent application costs		5,449			5,140			(309	)
General and administrative expenses		262,141			375,796			113,655
Research and product development, net of investment tax credits		186,867			275,916			89,049
Total operating expenses		460,410			665,020			204,610
Operating Loss		(460,410	)		(665,020	)		204,610
Other expenses
Interest expense and bank charges, net		392,511			379,836			(12,675	)
Loss on change in value of derivative liability		643,194			247,249			(395,945	)
Loss on foreign exchange transactions		53,082			21,664			(31,418	)

Net loss	$	(1,549,197	)	$	(1,313,769	)	$	(235,428	)

Revenues

During the nine months ended July 31, 2015 and 2014, we generated no revenues.

Operating expenses

Operating expenses include the costs to a) develop and patent a method for controlling the delivery of compounds to a chemical reaction; b) develop the QL Care Analyzer, a small, automated, robust and proprietary point of care testing device; and, c) custom paramagnetic beads through our proprietary method which improves their light collection. In addition, the Company is in the process of adapting test products for the Point Of Care (“POC”) disposable, single-use cartridge-format. Detailed manufacturing specifications and costing have been created and custom manufacturers have been sourced.

General and administrative expenses

General and administrative expenses consist primarily of compensation to officers, occupancy costs, professional fees, listing costs and other office expenses. The decrease in general and administrative expenses is attributable primarily to a decrease in consulting fees and personnel costs.

Research and product development, net of investment tax credits

Research and development expenses consist primarily of salaries and wages paid to officers and employees engaged in those activities and supplies consumed therefor. Research and development expenses have reduced from the previous year through a reduction in staff.

Interest expense and bank charges

Interest expense consists primarily of interest on notes and debt discount amortization on those notes.

Three months ended July 31, 2015 as compared to three months ended July 31, 2014

	Three Months
	Ended July 31,
	2015			2014			$ Change

Revenue	$	-		$	-		$	-

Operating expenses:
Depreciation of property and equipment		2,061			2,740			679
Amortization of patent application costs		788			1,724			936
General and administrative expenses		46,626			107,751			61,125
Research and product development, net of investment tax credits		50,430			85,241			34,811
Total operating expenses		99,905			197,456			97,551
Operating Loss		(99,905	)		(197,456	)		97,551
Other expenses (income)
Interest expense and bank charges, net		130,118			142,256			12,138
Loss on change in value of derivative liability		314,345			246,430			(67,915	)
Loss (gain) on foreign exchange transactions		67,122			(20,515	)		(87,637	)

Net (loss)	$	(611,490	)	$	(565,627	)	$	(45,863	)

Revenues

During the three months ended July 31, 2015 and 2014, we generated no revenues.

Operating expenses

Operating expenses include the costs to a) develop and patent a method for controlling the delivery of compounds to a chemical reaction; b) develop the QL Care Analyzer, a small, automated, robust and proprietary point of care testing device; and, c) custom paramagnetic beads through our proprietary method which improves their light collection. In addition, the Company is in the process of adapting test products for the POC disposable, single-use cartridge-format. Detailed manufacturing specifications and costing have been created and custom manufacturers have been sourced.

General and administrative expenses

Research and product development, net of investment tax credits

Research and development expenses consist primarily of salaries and wages paid to officers and employees engaged in those activities and supplies consumed therefor. Research and development expenses in 2015 are lower than for the same period in 2014 due to the reduction in staff in the current period.

Interest expense and bank charges

Interest expense consists primarily of interest on Notes and debt discount amortization on those Notes.

Liquidity and Capital Resources

We have not generated significant revenues since inception. We incurred a net loss of approximately $1,549,000 and a cash flow deficiency from operating activities of $473,486 for the nine months ended July 31, 2015. We have not yet established an ongoing source of revenues sufficient to cover our operating costs and allow us to continue as a going concern. We have funded our activities to date almost exclusively from debt and equity financings. These matters raise substantial doubt about our ability to continue as a going concern.

We will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of our products, to fund the ongoing operations and to commence sales and marketing efforts. Our plans include financing activities such as private placements of our common stock and issuances of convertible debt instruments. We are also actively pursuing industry collaboration, including product licensing and specific project financing.

We believe we will be successful in obtaining the necessary financing to fund our operations, meet revenue projections and manage costs; however, there are no assurances that such additional funding will be achieved and that we will succeed in obtaining the funding to support our future operations.

Seasonality

We do not believe that our business is subject to seasonal trends or inflation. On an ongoing basis, we will attempt to minimize any effect of inflation on our operating results by controlling operating costs.

Recent Accounting Pronouncements

In June 2014, the Financial Accounting Standards Board issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of the inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company has effective early adoption of ASU 2014-10 in these interim condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

N/A.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures:

Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) of the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. A control system, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Because of the inherent limitations in all control systems, internal control over financial reporting may not prevent or detect misstatements. The design and operation of a control system must also reflect that there are resource constraints and management is necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls.

Our management assessed the effectiveness of our internal control over disclosure controls and procedures for the quarter ended July 31, 2015, based on the criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on such assessment, our management concluded that during the period covered by this report, our internal control over financial reporting was not effective. Management has identified the following material weaknesses in our internal control over financial reporting:

	●	Lack of documented policies and procedures;

	●	Lack of effective separation of duties, which includes monitoring controls, between the members of management;

	●	Lack of resources to account for complex and unusual transactions; and

	●	Lack of effective review of consolidated financial statements.

Management is currently evaluating what steps can be taken in order to address these material weaknesses.

(b) Changes in Internal Control over Financial Reporting:

During the fiscal quarter ended July 31, 2015, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

On June 3, 2015, JMJ Financial filed a suit in Florida court demanding payment of its outstanding note payable in the amount of $77,235 for failure to convert a portion of its note into 1,800,000 common shares. The parties have agreed to resolve the matter by the Company agreeing with JMJ Financial to repay the $77,235 in equal monthly installments of $6,436 over twelve (12) months commencing June 23, 2015. The Company may elect to pay any of the scheduled payments in the form of common stock calculated using the lowest closing price of the common stock in the five trading days prior to the Company delivering the common stock. The suit was subsequently withdrawn June 19, 2015.

Item 1A. Risk Factors

Not Applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table summarizes sales of unregistered securities by the Company during the fiscal quarter ended July 31, 2015:

Investor	Investment Type	Am’t of Debt Converted ($)		Conversion Price/Share		Conversion Date	Shares issued Pursuant to Conversion

Iliad Research	Convertible Note	$	15,000	$	0.006	5/12/15		2,457,002
Sub-Total		$	15,000					2,457,002

LG Capital	Convertible Note	$	26,000	$	0.009	5/8/15		2,983,381
Sub-Total		$	26,000					2,983,381

Adar Bays	Convertible Note	$	5,000	$	0.011	5/11/15		453,721
Adar Bays	Convertible Note	$	7,500	$	0.016	6/4/15		483,765
Adar Bays	Convertible Note	$	7,000	$	0.008	6/23/15		862,069
Sub-Total		$	19,500					1,799,555

TOTALS		$	60,500					7,239,938

All of the above-referenced sales were exempt from registration pursuant to Section 4 (a)(2) of the Securities Act of 1933.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits

31.1	Section 302 Certification of Chief Executive Officer. ^*

31.2	Section 302 Certification of Chief Financial Officer.^*

32.1	Section 906 Certification of Chief Executive Officer and Chief Financial Officer.^*

101 INS	XBRL Instance Document^**

101 SCH	XBRL Schema Document^**

101 CAL	XBRL Calculation Linkbase Document^**

101 LAB	XBRL Label Linkbase Document^**

101 PRE	XBRL Presentation Linkbase Document^**

101 DEF	XBRL Definition Linkbase Document^**

* Filed herewith

** In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise Exhibit 101 in this Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed.”

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOGENICS HOLDINGS INC.

Date: September 23, 2015	By:	/s/ Yahia Gawad
	Name:	Yahia Gawad
	Title:	Chief Executive Officer


Date: September 23, 2015	By:	/s/ James Essex
	Name:	James Essex
	Title:	Chief Financial Officer

EXHIBIT INDEX

31.1	Section 302 Certification of Chief Executive Officer.^*

31.2	Section 302 Certification of Chief Financial Officer.^*

32.1	Section 906 Certification of Chief Executive Officer and Chief Financial Officer.^*

101 INS	XBRL Instance Document ^**

101 SCH	XBRL Schema Document ^**

101 CAL	XBRL Calculation Linkbase Document ^**

101 LAB	XBRL Label Linkbase Document ^**

101 PRE	XBRL Presentation Linkbase Document ^**

101 DEF	XBRL Definition Linkbase Document ^**

* Filed herewith

** In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise Exhibit 101 in this Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed.”

EXHIBIT 31.1

SECTION 302 CERTIFICATION

I, Yahia Gawad, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended July 31, 2015 of CardioGenics Holdings Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in the report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 23, 2015

	/s/ Yahia Gawad
	Yahia Gawad
	Chief Executive Officer

EXHIBIT 31.2

SECTION 302 CERTIFICATION

I, James Essex, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended July 31, 2015 of CardioGenics Holdings Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 23, 2015

	/s/ James Essex
	James Essex
	Chief Financial Officer

EXHIBIT 32.1

Section 906 Certification by the Chief Executive Officer and Chief Financial Officer

Each of Yahia Gawad, Chief Executive Officer, and James Essex, Chief Financial Officer, of CardioGenics Holdings Inc., a Nevada corporation (the “Company”) hereby certifies pursuant to 18 U.S.C. ss. 1350, as added by ss. 906 of the Sarbanes-Oxley Act of 2002, that, to their knowledge:

(1) The Company’s periodic report on Form 10-Q for the period ended July 31, 2015 (“Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operation of the Company.

By:	/s/ Yahia Gawad	By:	/s/ James Essex
Name:	Yahia Gawad	Name:	James Essex
Title:	Chief Executive Officer	Title:	Chief Financial Officer

Date:	September 23, 2015